Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Novartis
US Army
Baxter
Mallinckrodt
AstraZeneca
McKinsey
Farmers Insurance
QuintilesIMS

Generated: October 22, 2017

DrugPatentWatch Database Preview

Luitpold Company Profile

« Back to Dashboard

What is the competitive landscape for LUITPOLD, and what generic alternatives to LUITPOLD drugs are available?

LUITPOLD has ninety-five approved drugs.

There are four US patents protecting LUITPOLD drugs.

There are fifty-six patent family members on LUITPOLD drugs in thirty countries and ninety-one supplementary protection certificates in eleven countries.

Summary for Applicant: Luitpold

International Patents:56
US Patents:4
Tradenames:76
Ingredients:73
NDAs:95
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold
HYDRALAZINE HYDROCHLORIDE
hydralazine hydrochloride
INJECTABLE;INJECTION040136-001Jun 30, 1997APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold
VENOFER
iron sucrose
INJECTABLE;INTRAVENOUS021135-003Mar 29, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride
INJECTABLE;INJECTION083198-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold Pharms Inc
INJECTAFER
ferric carboxymaltose
INJECTABLE;INTRAVENOUS203565-001Jul 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Luitpold
VERAPAMIL HYDROCHLORIDE
verapamil hydrochloride
INJECTABLE;INJECTION070617-001Nov 12, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
CALCITRIOL
calcitriol
INJECTABLE;INJECTION075746-002Sep 26, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
TRANEXAMIC ACID
tranexamic acid
INJECTABLE;INJECTION201885-001Aug 10, 2011APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold
GRANISETRON HYDROCHLORIDE
granisetron hydrochloride
INJECTABLE;INJECTION091274-001Sep 22, 2010APRXNoNo► Subscribe► Subscribe► Subscribe
Luitpold
THIAMINE HYDROCHLORIDE
thiamine hydrochloride
INJECTABLE;INJECTION080667-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Luitpold
AMINOPHYLLINE
aminophylline
INJECTABLE;INJECTION087240-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Luitpold

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Luitpold
DEXFERRUM
iron dextran
INJECTABLE;INJECTION040024-001Feb 23, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Luitpold

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,549Methods and compositions for administration of iron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Luitpold Drugs

Country Document Number Estimated Expiration
Japan5289413► Subscribe
Japan2006505638► Subscribe
China100480275► Subscribe
Slovenia1554315► Subscribe
South Korea20080082674► Subscribe
European Patent Office2626074► Subscribe
Norway20052410► Subscribe
Peru05712004► Subscribe
Saudi Arabia2095► Subscribe
World Intellectual Property Organization (WIPO)2004037865► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Luitpold Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80018Netherlands► SubscribePRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318
00095Netherlands► SubscribePRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
00117Netherlands► SubscribePRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
2009004,C0770388Lithuania► SubscribePRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
923Luxembourg► SubscribePRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C0005Belgium► SubscribePRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711
C/GB08/020United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
2009 00017Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Covington
Fish and Richardson
McKesson
UBS
Dow
AstraZeneca
Fuji
Boehringer Ingelheim
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot